PALI

Palisade Bio Inc

1.12

Nov 05 • 11:14 AM ET -0.13 (-10.40%)

Healthcare Biotechnology USA Micro NASD

Peers: ABVX SYRE IMUX ANAB PTGX ARQT MCRB ALMS ENTX ABBV

| Held by: VTI IWM VXF IWN VTWO IWC SURI ITOT IWO AVSC

Index	RUT
Market Cap	195.18M
Enterprise Value	70.01M
Income	-31.94M
Sales	0.50M
Book/sh	0.70
Cash/sh	0.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Dec 20, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	390.37
P/B	1.60
P/C	1.56
P/FCF	-
EV/EBITDA	-
EV/Sales	140.03
Quick Ratio	24.25
Current Ratio	24.25
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.54
EPS next Y	-0.28
EPS next Q	-0.06
EPS this Y	25.33%
EPS next Y	-25.89%
EPS next 5Y	-3.67%
EPS past 3/5Y	89.33% 88.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	91.31%
Sales Y/Y TTM	-
EPS Q/Q	91.38%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	4.21% -

Insider Own	7.77%
Insider Trans	-0.39%
Inst Own	100.97%
Inst Trans	7.79%
ROA	-47.68%
ROE	-51.37%
ROIC	-26.24%
Gross Margin	-0.40%
Oper. Margin	-7069.80%
Profit Margin	-6388.20%
SMA20	-15.68%
SMA50	-29.23%
SMA200	-39.11%
Trades

Shs Outstand	173.60M
Shs Float	160.72M
Short Float	19.75%
Short Ratio	10.46
Short Interest	31.75M
52W High	2.86 -60.77%
52W Low	1.08 3.70%
Volatility	9.01% 8.19%
ATR (14)	0.11
RSI (14)	33.96
Beta	1.62
Rel Volume	1.29
Avg Volume	3.03M
Volume	1,186,127

Perf Week	-5.88%
Perf Month	-24.32%
Perf Quarter	-46.92%
Perf Half Y	-43.72%
Perf YTD	-52.34%
Perf Year	-33.33%
Perf 3Y	-87.01%
Perf 5Y	-99.95%
Perf 10Y	-100.00%
Recom	1.09
Target Price	10.00
Prev Close	1.25
Price	1.12
Change %	-10.40%

Consensus

Strong Buy

Avg. Price Target

$10.00

Implied Upside

+792.9%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 09, 2026	Initiated	RRaymond James	Outperform	$6	+435.7%
Jul 23, 2026	Initiated	OOppenheimer	Outperform	$8	+614.3%
Apr 09, 2026	Initiated	WWolfe Research	Outperform	$7	+525.0%
Mar 26, 2026	Initiated	HH.C. Wainwright	Buy	$7	+525.0%
Feb 25, 2026	Initiated	SStifel	Buy	$5	+346.4%
Jan 09, 2026	Initiated	RB. Riley Securities	Buy	$7	+525.0%
Dec 29, 2025	Initiated	PPiper Sandler	Overweight	$25	+2,132.1%

Oct-28-26 08:32AM	Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire)
Oct-20-26 08:05AM	Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 (GlobeNewswire) +6.72%
Oct-12-26 08:05AM	Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn's Disease at ACG 2026 (GlobeNewswire)
Sep-28-26 08:50AM	Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 (GlobeNewswire)
Sep-23-26 08:45AM	Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance (GlobeNewswire) -5.33%
08:35AM	Loading…
Sep-22-26 08:35AM	Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD (GlobeNewswire)
Sep-21-26 09:00AM	Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +6.29%
Sep-03-26 09:00AM	Palisade Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-26 04:20PM	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development (GlobeNewswire)
Jul-10-26 09:00AM	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum (GlobeNewswire)
Jun-29-26 01:49PM	PALI Stock Heads For Best Day In Seven Months Whats Driving Todays Rally? (Stocktwits) +17.99%
08:30AM	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis (GlobeNewswire)
Jun-11-26 08:45AM	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors (GlobeNewswire) +5.95%
Jun-09-26 08:45AM	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium (GlobeNewswire)
May-27-26 09:00AM	Palisade Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
04:15PM	Loading…
May-12-26 04:15PM	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 (GlobeNewswire)
May-05-26 08:30AM	Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis (GlobeNewswire) -7.51%
Apr-16-26 08:50AM	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 (GlobeNewswire)
Apr-08-26 09:00AM	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference (GlobeNewswire)
Mar-30-26 04:01PM	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease (GlobeNewswire) -11.00%
Mar-02-26 09:00AM	Palisade Bio Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 06:30AM	Palisade Bio Details PALI-2108 UC, Crohns Plans and Cash Runway Into 2029 at Oppenheimer Conference (MarketBeat)
Feb-23-26 08:40AM	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 (GlobeNewswire)
Feb-17-26 08:45AM	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board (GlobeNewswire)
Feb-09-26 09:00AM	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire)
Feb-05-26 08:45AM	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.06%
Jan-29-26 08:45AM	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board (GlobeNewswire)
Jan-16-26 08:30AM	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences (GlobeNewswire) -5.14%
Jan-07-26 08:15AM	Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 (GlobeNewswire) +5.21%
Dec-30-25 08:35AM	Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 (GlobeNewswire)
07:52AM	Loading…
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +15.35%
Dec-25-25 10:37AM	Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results (Insider Monkey)
Dec-19-25 12:00PM	Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know (Zacks) +9.58%
Dec-02-25 08:45AM	Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development (GlobeNewswire)
Nov-25-25 08:45AM	Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) -5.70%
Nov-10-25 09:55AM	Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher (Zacks) +5.36%
Nov-06-25 12:00PM	All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy (Zacks)
Oct-28-25 08:45AM	Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations (GlobeNewswire) +11.45%
Oct-20-25 08:45AM	Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire) +6.90%
Oct-13-25 08:45AM	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 (GlobeNewswire) -7.50%
Oct-09-25 05:00PM	Palisade Bio Announces Cancellation of Special Meeting of Stockholders (GlobeNewswire)
Oct-02-25 04:05PM	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option (GlobeNewswire) +29.77% -5.88%
Oct-01-25 09:20AM	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +52.38%
Sep-26-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +16.20%
Sep-18-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Sep-17-25 09:00AM	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data (GlobeNewswire)
Sep-05-25 08:45AM	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire)
Aug-25-25 09:00AM	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 (GlobeNewswire) -8.46%
Aug-11-25 07:04AM	Palisade reports outcomes from Phase Ib ulcerative colitis study (Clinical Trials Arena) -6.34%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.16%
09:15AM	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 (GlobeNewswire)
Jul-31-25 08:45AM	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China (GlobeNewswire)
Jul-30-25 06:30AM	PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR (PR Newswire)
Jul-23-25 08:00PM	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million (GlobeNewswire) +41.86% -9.02%
Jul-22-25 08:45AM	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire) -9.20%
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-09-25 08:45AM	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors (GlobeNewswire) +5.41%
May-27-25 08:30AM	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis (GlobeNewswire)
May-06-25 08:30AM	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases (GlobeNewswire) +6.07%
May-01-25 08:30AM	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit (GlobeNewswire)
Apr-09-25 08:30AM	Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire)
Mar-14-25 08:30AM	Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM	Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM	Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM	Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM	Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM	Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM	Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM	Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
Jan-16-25 08:00AM	Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Dec-17-24 08:30AM	Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board (GlobeNewswire)
Dec-13-24 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Donald Allen	Director	Oct 02 '26	Buy	1.46	10,000	14,600	1,590,294	Oct 05 05:20 PM
Williams Donald Allen	Director	Oct 01 '26	Buy	1.42	10,000	14,200	1,580,294	Oct 05 05:20 PM
Baltera Robert Jr.	Director	Jul 09 '26	Buy	1.96	25,000	48,900	461,904	Jul 10 06:14 PM
Baltera Robert Jr.	Director	Jul 08 '26	Buy	1.99	20,000	39,798	436,904	Jul 10 06:14 PM
Baltera Robert Jr.	Director	Jul 07 '26	Buy	2.03	30,000	61,044	416,904	Jul 08 06:56 PM
Baltera Robert Jr.	Director	Jul 06 '26	Buy	2.05	20,000	41,040	386,904	Jul 08 06:56 PM
Jones Mitchell Lawrence	Chief Medical Officer	Jul 07 '26	Sale	2.05	51,880	106,536	94,009	Jul 08 06:52 PM
Finley John David	CEO, CFO	Jul 07 '26	Option Exercise	0.70	133	93	217,688	Jul 08 06:49 PM
Finley John David	CEO, CFO	Jul 07 '26	Sale	2.07	146,798	303,343	217,555	Jul 08 06:49 PM
Jones Mitchell Lawrence	Officer	Jul 07 '26	Proposed Sale	2.04	53,000	108,120		Jul 07 05:18 PM
Finley John David	Officer	Jul 07 '26	Proposed Sale	2.07	146,798	303,343		Jul 07 04:59 PM
Baltera Robert Jr.	Director	Jul 01 '26	Buy	1.98	20,000	39,600	356,904	Jul 06 07:48 PM
Baltera Robert Jr.	Director	Jul 02 '26	Buy	1.98	10,000	19,800	366,904	Jul 06 07:48 PM
Jones Mitchell Lawrence	Chief Medical Officer	Feb 12 '26	Sale	1.75	1,989	3,481	13,263	Feb 13 08:10 PM
Finley John David	CEO, CFO	Feb 12 '26	Sale	1.75	3,896	6,818	27,353	Feb 13 08:07 PM
Williams Donald Allen	Director	Jan 16 '26	Buy	1.67	5,000	8,356	10,728	Jan 21 04:05 PM
Williams Donald Allen	Director	Jan 09 '26	Buy	1.88	5,000	9,400	5,728	Jan 13 09:43 PM

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.

CEOMr. J. D. Finley

Ph.D.Dr. Mitchell Lawrence Jones M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your Finviz experience